Status:
COMPLETED
Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
CGD
Eligibility:
All Genders
18-26 years
Brief Summary
Background: People who get chronic illnesses as children are living longer. When they turn 18, they switch from pediatric care to adult care. This can be a difficult change. Chronic Granulomatous Dis...
Detailed Description
Children with chronic illnesses are thriving well into adulthood due to ongoing medical advances. Many healthy and typically developing 18-year-olds should be able to manage a transition from pediatri...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- 18 to 24 years of age during January 1, 2011 to December 31, 2012
- Documented diagnosis of CGD
- Enrolled in one of the following three NIAID protocols that investigate CGD (and other immunodeficiencies):
- Detection and Characterization of Host Defense Defects (93-I-0119), PI: Dr. Steven Holland
- Screening and Baseline Assessment of Patients with Abnormalities of Immune Function (05-I-0213), PI: Dr. Harry Malech
- Screening Protocol for Detection and Characterization of Infections and Infection (07-I-0033), PI: Dr. Steven Holland
- Record of a visit to NIH prior to 18th birthday and at least one visit during January 1, 2011 to December 31, 2012
- Health status sufficient to participate in an interview, as determined by patient self-report at the start of the interview.
- Fluency in English
Exclusion
Key Trial Info
Start Date :
March 26 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2017
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT02233036
Start Date
March 26 2014
End Date
January 10 2017
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi
Bethesda, Maryland, United States, 20892